BackCitius Oncology Overview
Citius Oncology Inc.

Citius Oncology Debt to Equity

Latest debt-to-equity ratio for Citius Oncology: 0.11 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.11

Debt to Equity

0.11

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Average Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Citius Oncology (CTOR) FAQ

Citius Oncology's debt-to-equity ratio stands at 0.11. That is below the sector sector average of 0.14. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Citius Oncology sits lower the its sector benchmark (0.14) with a debt-to-equity ratio of 0.11. That is roughly 21.8% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 0.11 is attractive depends on Citius Oncology's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Citius Oncology's debt-to-equity ratio evolved across reporting periods, while the comparison chart places CTOR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.